A critical appraisal of lithium’s efficacy and effectiveness: the last 60 years
Authors:
- 1 June 2009
- journal article
- review article
- Published by Wiley in Bipolar Disorders
- Vol. 11 (s2) , 10-19
Abstract
The history that depicts the evaluation of lithium’s efficacy presents an interesting contrast: on the one hand, conviction that, of all psychotropic drugs, lithium has the best demonstrated efficacy; on the other hand, repeated attempts to question it. Those contesting lithium’s stabilizing abilities have argued from several angles, for example that the proof was methodologically incorrect or insufficient, that the number of responders is small, or that the response is poor in practice and does not last. But there is a good explanation for this paradox. While the early challenges to lithium’s value in recurrent mood disorders reflected mainly that psychiatry had not yet developed a methodology suitable for testing long‐term efficacy, more recent questioning has resulted mostly from retesting its efficacy and effectiveness in a substantially broadened bipolar spectrum, outside the classical diagnosis. Lithium, however, continues to stabilize very well the patients suffering from typical bipolar disorder—the condition for which its efficacy was originally demonstrated. More recently, lithium has also proven to dramatically reduce suicidal behavior and mortality and to augment markedly the efficacy of antidepressants in unresponsive patients.Keywords
This publication has 71 references indexed in Scilit:
- Long-Term Effectiveness of Lithium in Bipolar DisorderThe Journal of Clinical Psychiatry, 2008
- Divalproex, lithium and suicide among Medicaid patients with bipolar disorderJournal of Affective Disorders, 2008
- The Impact of Lithium Long-Term Medication on Suicidal Behavior and Mortality of Bipolar PatientsArchives of Suicide Research, 2005
- Suicide in 406 Mood-Disorder Patients With and Without Long-Term Medication: A 40 to 44 Years' Follow-UpArchives of Suicide Research, 2005
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- The effect of long‐term lithium treatment on the mortality of patients with manic‐depressive and schizoaffective illness*Acta Psychiatrica Scandinavica, 1992
- Recurrence of affective illness after withdrawal of long-term lithium treatmentActa Psychiatrica Scandinavica, 1983
- III. A DOUBLE BLIND STUDY OF THE PROPHYLACTIC EFFECT OF LITHIUM IN MANIC‐DEPRESSIVE DISEASEActa Psychiatrica Scandinavica, 1977
- PROPHYLACTIC LITHIUM IN RECURRENT AFFECTIVE DISORDERSThe Lancet, 1972
- PROPHYLACTIC LITHIUM: ANOTHER THERAPEUTIC MYTH?The Lancet, 1968